MAPT and Alzheimer disease: Given the high concordance between CSF Aβ42/40 or Aβ42/P-tau (>90%) has with Amyloid PET [26], the clear benefits of testing for amyloid status shown by this study should also be relevant for CSF AD biomarkers.